{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:13:50Z","timestamp":1784121230903,"version":"3.55.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1097\/fpc.0000000000000334","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T18:53:01Z","timestamp":1523386381000},"page":"117-124","source":"Crossref","is-referenced-by-count":15,"title":["A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China"],"prefix":"10.1097","volume":"28","author":[{"given":"Heng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-014-0082-z","article-title":"Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling","volume":"27","author":"Liu","year":"2014","journal-title":"J Nephrol"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","article-title":"Current and future therapies for gout","volume":"18","author":"Pascart","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Europe","volume":"6","author":"Genin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"565320","DOI":"10.1155\/2014\/565320","article-title":"HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review","volume":"2014","author":"Cheng","year":"2014","journal-title":"J Immunol Res"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2217\/pgs.11.131","article-title":"Allopurinol pharmacogenetics: assessment of potential clinical usefulness","volume":"12","author":"Zineh","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/CIA.S5476","article-title":"Management of hyperuricemia in gout: focus on febuxostat","volume":"5","author":"Reinders","year":"2010","journal-title":"Clin Interv Aging"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.12050","article-title":"HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region","volume":"16","author":"Yeo","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Goncalo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/cts.12365","article-title":"Genotyping HLA-B*5801 for allopurinol-induced severe cutaneous adverse reactions: an accurate and prompt method","volume":"8","author":"Cheng","year":"2015","journal-title":"Clin Transl Sci"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/pgs.15.125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore","volume":"16","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3899\/jrheum.120803","article-title":"HLA-B*5801 should be used to screen for risk of Stevens\u2013Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy","volume":"40","author":"Lee","year":"2013","journal-title":"J Rheumatol"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis","volume":"20","author":"Yu","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0378-6323.148566","article-title":"Drug eruptions induced by allopurinol associated with HLA-B*5801","volume":"81","author":"Zeng","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:24:21Z","timestamp":1620951861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201805000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000334","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}